세계의 차세대 시퀀싱 시장 - 규모, 점유율, 동향 분석 보고서 : 기술별, 제품별, 용도별, 워크플로우별, 최종 용도별, 지역별 부문 예측(2025-2033년)

Next Generation Sequencing Market Summary

The global next-generation sequencing market size was estimated at USD 9.56 billion in 2024 and is anticipated to reach USD 42.25 billion by 2033, growing at a CAGR of 18.0% from 2025 to 2033. This growth is driven by the increasing demand for advanced genomic research, rising applications of next-generation sequencing (NGS) in clinical diagnostics, and ongoing technological advancements in sequencing platforms.

Global Next-Generation Sequencing Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the next-generation sequencing market based on technology, product, workflow, end-use, and region.

• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• WGS
• Whole Exome Sequencing
• Targeted Sequencing & Resequencing
  • DNA-based
  • RNA-based
• Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Platform
  • Sequencing
  • Data Analysis
• Consumables
  • Sample Preparation
  • Target Enrichment
  • Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
  • Diagnostics and Screening
  • Oncology Screening
  • Sporadic Cancer
  • Inherited Cancer
  • Companion Diagnostics
  • Other Diagnostics
  • Research Studies
• Clinical Investigation
  • Infectious Diseases
  • Inherited Diseases
  • Idiopathic Diseases
  • Non-Communicable/Other Diseases
• Reproductive Health
  • NIPT
  • Aneuploidy
  • Microdeletions
  • PGT
  • Newborn Genetic Screening
  • Single Gene Analysis
• HLA Typing/Immune System Monitoring
• Metagenomics, Epidemiology & Drug Development
• Agrigenomics & Forensics
• Consumer Genomics
• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Pre-Sequencing
  • Nucleic Acid Extraction
  • Library Preparation
• Sequencing
  • NGS Data Analysis
  • NGS Primary Data Analysis
  • NGS Secondary Data Analysis
  • NGS Tertiary Data Analysis
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Academic Research
• Clinical Research
• Hospitals & Clinics
• Pharma & Biotech Entities
• Other Users
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Technology Segment
  • 1.1.2. Product Segment
  • 1.1.3. Workflow Segment
  • 1.1.4. Application Segment
  • 1.1.5. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objective
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Trends and Outlook
• 3.4. Market Dynamics
  • 3.4.1. Market Drivers Analysis
    • 3.4.1.1. Decreasing costs for genetic sequencing
    • 3.4.1.2. Development of companion diagnostics and personalized medicine
    • 3.4.1.3. Rising clinical opportunity for NGS technology
    • 3.4.1.4. Technological advancements in cloud computing
  • 3.4.2. Market Restraint Analysis
    • 3.4.2.1. Lack of computational efficiency for data management
    • 3.4.2.2. Non-value-based NGS reimbursement policy and regulation status
    • 3.4.2.3. Challenges associated with NGS implementation
• 3.5. Market Analysis Tools
  • 3.5.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
  • 3.5.2. Porter's Five Forces Analysis

Chapter 4. Technology Business Analysis

• 4.1. Segment Dashboard
• 4.2. Next Generation Sequencing Data Analysis Market: Technology Movement Analysis
• 4.3. Targeted Sequencing & Resequencing
  • 4.3.1. Targeted Sequencing & Resequencing Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 4.3.2. DNA-Based Targeted Sequencing & Resequencing
    • 4.3.2.1. DNA-based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
  • 4.3.3. RNA-Based Targeted Sequencing & Resequencing
    • 4.3.3.1. RNA -based targeted sequencing & resequencing market estimates and forecast, 2021 - 2033 (USD Million)
• 4.4. Whole Genome Sequencing
  • 4.4.1. Whole Genome Sequencing Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 4.5. Whole Exome Sequencing
  • 4.5.1. Whole Exome Sequencing Market Estimates and Forecast, 2021 - 2033 (USD Million)

Chapter 5. Product Business Analysis

• 5.1. Segment Dashboard
• 5.2. Next Generation Sequencing Data Analysis Market: Product Movement Analysis
• 5.3. Platforms
  • 5.3.1. Platforms Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 5.3.2. Sequencing
    • 5.3.2.1. Sequencing Platforms Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 5.3.3. Data Analysis
    • 5.3.3.1. Data Analysis Platforms Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 5.4. Consumables
  • 5.4.1. Consumables Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 5.4.2. Sample Preparation
    • 5.4.2.1. Sample Preparation Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 5.4.3. Target Enrichment
    • 5.4.3.1. Target Enrichment Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 5.4.4. Others
    • 5.4.4.1. Others Market Estimates and Forecast, 2021 - 2033 (USD Million)

Chapter 6. Application Business Analysis

• 6.1. Segment Dashboard
• 6.2. Next Generation Sequencing Data Analysis Market: Application Movement Analysis
• 6.3. Oncology
  • 6.3.1. Oncology Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.3.2. Diagnostics & Screening
    • 6.3.2.1. Diagnostics & Screening Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 6.3.2.2. Oncology screening
      • 6.3.2.2.1. Oncology Screening Market Estimates and Forecast, 2021 - 2033 (USD Million)
      • 6.3.2.2.2. Sporadic Cancer Screening Market Estimates and Forecast, 2021 - 2033 (USD Million)
      • 6.3.2.2.3. Inherited Cancer Screening Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 6.3.2.3. Companion diagnostics
      • 6.3.2.3.1. Companion Diagnostics Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 6.3.2.4. Other Diagnostics
      • 6.3.2.4.1. Other Diagnostics Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.3.3. Research Studies
    • 6.3.3.1. Research Studies Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 6.4. Clinical Investigation
  • 6.4.1. Clinical Investigation Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.4.2. Infectious Diseases
    • 6.4.2.1. Infectious Diseases Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.4.3. Idiopathic Diseases
    • 6.4.3.1. Idiopathic Diseases Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.4.4. Inherited Diseases
    • 6.4.4.1. Inherited Diseases Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.4.5. Non-communicable/other Diseases
    • 6.4.5.1. Reproductive Health Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 6.5. Reproductive Health
  • 6.5.1. Clinical Investigation Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.5.2. NIPT
    • 6.5.2.1. NIPT Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 6.5.2.2. Aneuploidy
      • 6.5.2.2.1. Aneuploidy Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 6.5.2.3. Microdeletions
      • 6.5.2.3.1. Microdeletions Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.5.3. PGT
    • 6.5.3.1. PGT Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.5.4. Newborn Genetic Screening
    • 6.5.4.1. Newborn Genetic Screening Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.5.5. Single Gene Analysis Market
    • 6.5.5.1. Single Gene Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 6.6. HLA Typing/Immune System Monitoring
  • 6.6.1. HLA Typing/Immune System Monitoring Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 6.7. Metagenomics, Epidemiology & Drug Development
  • 6.7.1. Metagenomics, Epidemiology & Drug Development Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 6.8. Agrigenomics & Forensics
  • 6.8.1. Agrigenomics & Forensics Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 6.9. Consumer Genomics
  • 6.9.1. Consumer Genomics Market Estimates and Forecast, 2021 - 2033 (USD Million)

Chapter 7. Workflow Business Analysis

• 7.1. Segment Dashboard
• 7.2. Next Generation Sequencing Data Analysis Market: Workflow Movement Analysis
• 7.3. Presequencing
  • 7.3.1. Presequencing Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 7.3.2. Nucleic Acid Extraction
    • 7.3.2.1. Nucleic Acid Extraction Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 7.3.3. Library Preparation
    • 7.3.3.1. Library Preparation Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 7.4. Sequencing
  • 7.4.1. Sequencing Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 7.5. Data Analysis
  • 7.5.1. Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 7.5.2. Primary Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 7.5.2.1. Primary Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 7.5.3. Secondary Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 7.5.3.1. Secondary Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 7.5.4. Tertiary Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 7.5.4.1. Tertiary Data Analysis Market Estimates and Forecast, 2021 - 2033 (USD Million)

Chapter 8. End Use Business Analysis

• 8.1. Segment Dashboard
• 8.2. Next Generation Sequencing Market: End - Use Movement Analysis
• 8.3. Academic Research
  • 8.3.1. Academic Research Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 8.4. Clinical Research
  • 8.4.1. Clinical Research Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 8.5. Hospitals & Clinics
  • 8.5.1. Hospitals & Clinics Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 8.6. Pharmaceutical & Biotech Entities
  • 8.6.1. Pharmaceutical & Biotech Entities Market Estimates and Forecast, 2021 - 2033 (USD Million)
• 8.7. Other Users
  • 8.7.1. Other Users Market Estimates and Forecast, 2021 - 2033 (USD Million)

Chapter 9. Regional Business Analysis

• 9.1. Next Generation Sequencing Market Share By Region, 2024 & 2033
• 9.2. North America
  • 9.2.1. North America next generation sequencing market, 2021 - 2033 (USD Million)
  • 9.2.2. U.S.
    • 9.2.2.1. Key country dynamics
    • 9.2.2.2. U.S. next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.2.3. Target disease prevalence
    • 9.2.2.4. Competitive scenario
    • 9.2.2.5. Regulatory framework
    • 9.2.2.6. Reimbursement scenario
  • 9.2.3. Canada
    • 9.2.3.1. Key country dynamics
    • 9.2.3.2. Canada next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.3.3. Target disease prevalence
    • 9.2.3.4. Competitive scenario
    • 9.2.3.5. Regulatory framework
    • 9.2.3.6. Reimbursement scenario
  • 9.2.4. Mexico
    • 9.2.4.1. Key country dynamics
    • 9.2.4.2. Mexico next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.4.3. Target disease prevalence
    • 9.2.4.4. Competitive scenario
    • 9.2.4.5. Regulatory framework
    • 9.2.4.6. Reimbursement scenario
  • 9.2.5. Europe
  • 9.2.6. Europe Next Generation Sequencing market, 2021 - 2033 (USD Million)
  • 9.2.7. Germany
    • 9.2.7.1. Key country dynamics
    • 9.2.7.2. Germany next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.7.3. Target disease prevalence
    • 9.2.7.4. Competitive scenario
    • 9.2.7.5. Regulatory framework
    • 9.2.7.6. Reimbursement scenario
  • 9.2.8. UK
    • 9.2.8.1. Key country dynamics
    • 9.2.8.2. UK next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.8.3. Target disease prevalence
    • 9.2.8.4. Competitive scenario
    • 9.2.8.5. Regulatory framework
    • 9.2.8.6. Reimbursement scenario
  • 9.2.9. France
    • 9.2.9.1. Key country dynamics
    • 9.2.9.2. France next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.9.3. Target disease prevalence
    • 9.2.9.4. Competitive scenario
    • 9.2.9.5. Regulatory framework
    • 9.2.9.6. Reimbursement scenario
  • 9.2.10. Italy
    • 9.2.10.1. Key country dynamics
    • 9.2.10.2. Italy next generation sequencing (NGS) market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.10.3. Target disease prevalence
    • 9.2.10.4. Competitive scenario
    • 9.2.10.5. Regulatory framework
    • 9.2.10.6. Reimbursement scenario
  • 9.2.11. Spain
    • 9.2.11.1. Key country dynamics
    • 9.2.11.2. Spain next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.11.3. Target disease prevalence
    • 9.2.11.4. Competitive scenario
    • 9.2.11.5. Regulatory framework
    • 9.2.11.6. Reimbursement scenario
  • 9.2.12. Denmark
    • 9.2.12.1. Key country dynamics
    • 9.2.12.2. Denmark next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.12.3. Target disease prevalence
    • 9.2.12.4. Competitive scenario
    • 9.2.12.5. Regulatory framework
    • 9.2.12.6. Reimbursement scenario
  • 9.2.13. Sweden
    • 9.2.13.1. Key country dynamics
    • 9.2.13.2. Sweden next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.13.3. Target disease prevalence
    • 9.2.13.4. Competitive scenario
    • 9.2.13.5. Regulatory framework
    • 9.2.13.6. Reimbursement scenario
  • 9.2.14. Norway
    • 9.2.14.1. Key country dynamics
    • 9.2.14.2. Norway next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.2.14.3. Target disease prevalence
    • 9.2.14.4. Competitive scenario
    • 9.2.14.5. Regulatory framework
    • 9.2.14.6. Reimbursement scenario
• 9.3. Asia Pacific
  • 9.3.1. Asia Pacific next generation sequencing market, 2021 - 2033 (USD Million)
  • 9.3.2. Japan
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Japan next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.3.2.3. Target disease prevalence
    • 9.3.2.4. Competitive scenario
    • 9.3.2.5. Regulatory framework
    • 9.3.2.6. Reimbursement scenario
  • 9.3.3. China
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. China next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.3.3.3. Target disease prevalence
    • 9.3.3.4. Competitive scenario
    • 9.3.3.5. Regulatory framework
    • 9.3.3.6. Reimbursement scenario
  • 9.3.4. India
    • 9.3.4.1. Key country dynamics
    • 9.3.4.2. India next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.3.4.3. Target disease prevalence
    • 9.3.4.4. Competitive scenario
    • 9.3.4.5. Regulatory framework
    • 9.3.4.6. Reimbursement scenario
  • 9.3.5. South Korea
    • 9.3.5.1. Key country dynamics
    • 9.3.5.2. South Korea next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.3.5.3. Target disease prevalence
    • 9.3.5.4. Competitive scenario
    • 9.3.5.5. Regulatory framework
    • 9.3.5.6. Reimbursement scenario
  • 9.3.6. Australia
    • 9.3.6.1. Key country dynamics
    • 9.3.6.2. Australia next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.3.6.3. Target disease prevalence
    • 9.3.6.4. Competitive scenario
    • 9.3.6.5. Regulatory framework
    • 9.3.6.6. Reimbursement scenario
  • 9.3.7. Thailand
    • 9.3.7.1. Key country dynamics
    • 9.3.7.2. Thailand next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.3.7.3. Target disease prevalence
    • 9.3.7.4. Competitive scenario
    • 9.3.7.5. Regulatory framework
    • 9.3.7.6. Reimbursement scenario
• 9.4. Latin America
  • 9.4.1. Latin America next generation sequencing market, 2021 - 2033 (USD Million)
  • 9.4.2. Brazil
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Brazil next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.4.2.3. Target disease prevalence
    • 9.4.2.4. Competitive scenario
    • 9.4.2.5. Regulatory framework
    • 9.4.2.6. Reimbursement scenario
  • 9.4.3. Argentina
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Argentina next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.4.3.3. Target disease prevalence
    • 9.4.3.4. Competitive scenario
    • 9.4.3.5. Regulatory framework
    • 9.4.3.6. Reimbursement scenario
• 9.5. MEA
  • 9.5.1. MEA next generation sequencing market, 2021 - 2033 (USD Million)
  • 9.5.2. South Africa
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. South Africa next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.5.2.3. Target disease prevalence
    • 9.5.2.4. Competitive scenario
    • 9.5.2.5. Regulatory framework
    • 9.5.2.6. Reimbursement scenario
  • 9.5.3. Saudi Arabia
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Saudi Arabia next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.5.3.3. Target disease prevalence
    • 9.5.3.4. Competitive scenario
    • 9.5.3.5. Regulatory framework
    • 9.5.3.6. Reimbursement scenario
  • 9.5.4. UAE
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. UAE next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.5.4.3. Target disease prevalence
    • 9.5.4.4. Competitive scenario
    • 9.5.4.5. Regulatory framework
    • 9.5.4.6. Reimbursement scenario
  • 9.5.5. Kuwait
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Kuwait next generation sequencing market estimates and forecasts, 2021 - 2033 (USD Million)
    • 9.5.5.3. Target disease prevalence
    • 9.5.5.4. Competitive scenario
    • 9.5.5.5. Regulatory framework
    • 9.5.5.6. Reimbursement scenario

Chapter 10. Competitive Landscape

• 10.1. Company/Competition Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Position Analysis, 2024
• 10.4. Company Profiles/Listing
  • 10.4.1. Illumina
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. F. Hoffman-La Roche Ltd.
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. QIAGEN
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. Thermo Fisher Scientific, Inc.
    • 10.4.4.1. Company overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. Bio-Rad Laboratories, Inc.
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product benchmarking
    • 10.4.5.4. Strategic initiatives
  • 10.4.6. Oxford Nanopore Technologies
    • 10.4.6.1. Company overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product benchmarking
    • 10.4.6.4. Strategic initiatives
  • 10.4.7. Revvity, Inc.
    • 10.4.7.1. Company overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product benchmarking
    • 10.4.7.4. Strategic initiatives
  • 10.4.8. PacBio
    • 10.4.8.1. Company overview
    • 10.4.8.2. Financial performance
    • 10.4.8.3. Product benchmarking
    • 10.4.8.4. Strategic initiatives
  • 10.4.9. Merk KGaA
    • 10.4.9.1. Company overview
    • 10.4.9.2. Financial performance
    • 10.4.9.3. Product benchmarking
    • 10.4.9.4. Strategic initiatives
  • 10.4.10. BGI
    • 10.4.10.1. Company overview
    • 10.4.10.2. Financial performance
    • 10.4.10.3. Product benchmarking
    • 10.4.10.4. Strategic initiatives